DISCO Application for the Improvement of Financial Outcomes in Patients With Hematologic Cancer
NCT04282343 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25
Last updated 2023-05-03
Summary
This phase II trial studies how well the DIScussion of COst (DISCO) application (app) works in improving financial outcomes in patients with hematologic cancer. The DISCO app is an electronic, highly scalable and tailorable education and communication intervention that may help researchers learn more about improving how patients and oncologists discuss cancer treatment costs
Conditions
- Chronic Lymphocytic Leukemia
- Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Plasma Cell Myeloma
Interventions
- BEHAVIORAL
-
The DISCO App
Patients will receive an individually-tailorable cancer treatment cost education and communication intervention delivered on an iPad just prior to meeting with their oncologist.
- BEHAVIORAL
-
Usual Care
Patients randomized to this arm will receive usual care.
Sponsors & Collaborators
-
Barbara Ann Karmanos Cancer Institute
lead OTHER
Principal Investigators
-
Lauren Hamel, PhD · Barbara Ann Karmanos Institute
Study Design
- Allocation
- RANDOMIZED
- Purpose
- HEALTH_SERVICES_RESEARCH
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2020-02-25
- Primary Completion
- 2022-10-21
- Completion
- 2022-10-21
Countries
- United States
Study Locations
More Related Trials
-
Predictive Clinical and Biological Parameters in Acute Leukemia, Myelodysplastic Syndromes and Myeloproliferative Disorders-HEMATO-BIO-IPC-2013-015
NCT02320656 ·Status: COMPLETED ·Phase: NA
-
Early Discharge and Outpatient Care After Chemotherapy in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
NCT00844441 ·Status: COMPLETED ·Phase: NA
-
Leridistim Compared With Filgrastim in Treating Older Patients With Acute Myeloid Leukemia
NCT00004215 ·Status: COMPLETED ·Phase: PHASE2
-
DTGM Fusion Protein in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia
NCT00003840 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT00112853 ·Status: COMPLETED ·Phase: PHASE1
-
Disrupting the Bone Marrow Microenvironment With G-CSF in Acute Lymphoblastic Leukemia
NCT01331590 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Considering alloHCT: Opportunities for Patient Reflection During Decision-Making Via Digital Stories
NCT07263074 ·Status: RECRUITING ·Phase: NA
-
Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
NCT00425477 ·Status: COMPLETED ·Phase: PHASE2
-
Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
NCT01567059 ·Status: COMPLETED ·Phase: PHASE2
-
AI-Assisted Acute Myeloid Leukemia Evaluation With the Leukemia End-to-End Analysis Platform (LEAP) Versus Clinician-Only Assessment
NCT07203885 ·Status: COMPLETED ·Phase: NA
-
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
NCT00075725 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment of Adult ALL With an MRD-directed Programme.
NCT00358072 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS
NCT03502668 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Integrative "Omics" Approaches for Leukemia Target Identification and Matched Therapeutic Intervention
NCT06626893 ·Status: RECRUITING ·Phase: NA
-
Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT01256398 ·Status: COMPLETED ·Phase: PHASE2
-
Prognostic Role of Minimal Residual Disease in Acute Myeloid Leukemia
NCT02714790 ·Status: COMPLETED
-
Treatment of Acute Lymphoblastic Leukemia HIGH RISK BCR / ABL NEGATIVE IN ADULTS
NCT01540812 ·Status: COMPLETED
-
Dexamethasone Added to Intensive Chemotherapy in Older Patients with Acute Myeloid Leukemia (AML)
NCT03609060 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.
NCT04425655 ·Status: TERMINATED ·Phase: PHASE2
-
Amifostine in Treating Patients With Myelodysplastic Syndrome
NCT00003048 ·Status: COMPLETED ·Phase: PHASE2
-
Personalized Medicine Program on Myelodysplastic Syndromes: Characterization of the Patient's Genome for Clinical Decision Making and Systematic Collection of Real World Data to Improve Quality of Health Care
NCT04212390 ·Status: COMPLETED
-
Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome
NCT01311258 ·Status: RECRUITING
-
MRD/Risk-oriented Therapy of Adult Ph- ALL Including Pegylated Asparaginase and Lineage-targeted Methotrexate
NCT02067143 ·Status: COMPLETED ·Phase: PHASE2
-
Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia
NCT00602771 ·Status: COMPLETED ·Phase: PHASE2
-
A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers
NCT06697600 ·Status: RECRUITING ·Phase: NA